April 3, 2018 / 12:04 PM / 21 days ago

BRIEF-AstraZeneca Says US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control

April 3 (Reuters) - AstraZeneca PLC:

* US FDA APPROVES BYDUREON FOR USE WITH BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES WITH INADEQUATE GLYCEMIC CONTROL

* 7 STUDY RESULTS SHOWED SIGNIFICANT HBA1C REDUCTION WHEN BYDUREON WAS ADDED TO INSULIN GLARGINE THERAPY VERSUS INSULIN GLARGINE ALONE​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below